Savara director David Ramsay acquires $416,250 in common stock

In a recent SEC filing, Savara Inc. (NASDAQ:SVRA), a $583 million market cap biotech company, disclosed that David A. Ramsay, a director at the company, purchased 150,000 shares of common stock. According to InvestingPro analysis, the company appears slightly undervalued at current levels, with a strong balance sheet showing more cash than debt. The transaction, which took place on March 31, 2025, was executed at a weighted average price of $2.775 per share, totaling $416,250. This acquisition increases Ramsay’s direct ownership to 2,513,642 shares. The purchase prices for the shares ranged from $2.75 to $2.80, as noted in the filing. While InvestingPro data shows the company is currently burning through cash rapidly, its healthy current ratio of 13.7 suggests strong short-term liquidity. Discover more insights and 7 additional key ProTips with an InvestingPro subscription, including detailed analysis available in the comprehensive Pro Research Report.

In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a drug aimed at treating autoimmune pulmonary alveolar proteinosis (aPAP). The company has requested a Priority Review, which could expedite the FDA’s review process. Savara’s CEO, Matt Pauls, expressed optimism about the drug’s efficacy, as clinical trials have shown significant improvements in lung function and quality of life for patients. The drug has also received various designations, including Fast Track and Breakthrough Therapy from the FDA. Analysts from H.C. Wainwright and JMP Securities have maintained positive outlooks on Savara, with price targets of $6 and $9, respectively, citing the potential approval and commercial launch of MOLBREEVI.

Additionally, Savara recently terminated its sales agreement with Evercore Group L.L.C., which allowed the sale of common stock through at-the-market offerings. This decision, effective in April 2025, does not incur penalties for the company. Meanwhile, retrospective data on molgramostim, the active ingredient in MOLBREEVI, suggests significant therapeutic benefits for aPAP patients, potentially reducing the need for whole lung lavage, a current treatment. Savara aims to file a Marketing Authorization Application in Europe by the end of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.